| 1 |
34304352 | Drug-interaction between paclitaxel and goshajinkigan extract and its constituents. | 2022 Jan |
2 |
| 2 |
34896780 | Lovastatin enhances chemosensitivity of paclitaxel-resistant prostate cancer cells through inhibition of CYP2C8. | 2022 Jan 22 |
2 |
| 3 |
33446524 | In Vitro Evidence of Potential Interactions between CYP2C8 and Candesartan Acyl-β-D-glucuronide in the Liver. | 2021 Apr |
2 |
| 4 |
33556367 | Differential inhibition of human CYP2C8 and molecular docking interactions elicited by sorafenib and its major N-oxide metabolite. | 2021 Apr 1 |
2 |
| 5 |
33649523 | Single nucleotide polymorphisms to predict taxanes toxicities and effectiveness in cancer patients. | 2021 Aug |
3 |
| 6 |
33775687 | Roles of CYP3A4, CYP3A5 and CYP2C8 drug-metabolizing enzymes in cellular cytostatic resistance. | 2021 May 1 |
1 |
| 7 |
34097831 | Carbon Monoxide Inhibits Cytochrome P450 Enzymes CYP3A4/2C8 in Human Breast Cancer Cells, Increasing Sensitivity to Paclitaxel. | 2021 Jun 24 |
1 |
| 8 |
32240873 | Dexamethasone simulates the anticancer effect of nano-formulated paclitaxel in breast cancer cells. | 2020 Jun |
4 |
| 9 |
32364081 | Paclitaxel Nanoparticles Induce Apoptosis and Regulate TXR1, CYP3A4 and CYP2C8 in Breast Cancer and Hepatoma Cells. | 2020 |
1 |
| 10 |
32505840 | Xiaoaiping injection enhances paclitaxel efficacy in ovarian cancer via pregnane X receptor and its downstream molecules. | 2020 Oct 28 |
1 |
| 11 |
32529309 | Physiologically-Based Pharmacokinetic Predictions of the Effect of Curcumin on Metabolism of Imatinib and Bosutinib: In Vitro and In Vivo Disconnect. | 2020 Jun 11 |
1 |
| 12 |
30520341 | Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure. | 2019 Jan |
3 |
| 13 |
31123858 | Impact of gene polymorphisms on the systemic toxicity to paclitaxel/carboplatin chemotherapy for treatment of gynecologic cancers. | 2019 Aug |
2 |
| 14 |
31540428 | Polymorphisms of CYP2C8 Alter First-Electron Transfer Kinetics and Increase Catalytic Uncoupling. | 2019 Sep 18 |
4 |
| 15 |
29223619 | Differential effects of hepatic cirrhosis on the intrinsic clearances of sorafenib and imatinib by CYPs in human liver. | 2018 Mar 1 |
1 |
| 16 |
29454704 | Selective inhibition of CYP2C8 by fisetin and its methylated metabolite, geraldol, in human liver microsomes. | 2018 Apr |
1 |
| 17 |
29689254 | Inhibitory Effects of Danshen components on CYP2C8 and CYP2J2. | 2018 Jun 1 |
1 |
| 18 |
30091920 | Discovery of a Potent and Selective Steroidal Glucocorticoid Receptor Antagonist (ORIC-101). | 2018 Sep 13 |
1 |
| 19 |
27599706 | Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes. | 2017 Apr |
1 |
| 20 |
28224612 | Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study. | 2017 Sep |
1 |
| 21 |
28238899 | Estimation of the Contribution of CYP2C8 and CYP3A4 in Repaglinide Metabolism by Human Liver Microsomes Under Various Buffer Conditions. | 2017 Sep |
1 |
| 22 |
28451807 | Increased risk of paclitaxel-induced peripheral neuropathy in patients using clopidogrel: a retrospective pilot study. | 2017 Aug |
1 |
| 23 |
26290405 | Effect of buffer conditions on CYP2C8-mediated paclitaxel 6α-hydroxylation and CYP3A4-mediated triazolam α- and 4-hydroxylation by human liver microsomes. | 2016 |
1 |
| 24 |
26446447 | Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60-year-old Caucasian woman with ovarian carcinoma. | 2016 Feb |
6 |
| 25 |
26467040 | CYP2C8 Is a Novel Target of Peroxisome Proliferator-Activated Receptor α in Human Liver. | 2016 Jan |
1 |
| 26 |
26551762 | The Role of CYP2C8 and CYP2C9 Genotypes in Losartan-Dependent Inhibition of Paclitaxel Metabolism in Human Liver Microsomes. | 2016 Jun |
3 |
| 27 |
26721703 | Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. | 2016 Jan |
1 |
| 28 |
27347418 | Potential drug interaction between paclitaxel and clopidogrel. | 2016 Jul |
1 |
| 29 |
27736846 | Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients. | 2016 Nov 22 |
2 |
| 30 |
27878971 | Pregnane X receptors regulate CYP2C8 and P-glycoprotein to impact on the resistance of NSCLC cells to Taxol. | 2016 Dec |
6 |
| 31 |
25424246 | Drug-drug Interaction between Losartan and Paclitaxel in Human Liver Microsomes with Different CYP2C8 Genotypes. | 2015 Jun |
3 |
| 32 |
25595597 | A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement. | 2015 Apr |
1 |
| 33 |
25936586 | In vitro inhibition of human cytochrome P450 by cudratricusxanthone A. | 2015 Jul |
1 |
| 34 |
26115084 | Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity. | 2015 |
2 |
| 35 |
24476576 | Pathway-dependent inhibition of paclitaxel hydroxylation by kinase inhibitors and assessment of drug-drug interaction potentials. | 2014 Apr |
3 |
| 36 |
24637579 | Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel--a review. | 2014 May |
1 |
| 37 |
24706167 | Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy. | 2014 May |
1 |
| 38 |
24800949 | Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies. | 2014 May 27 |
1 |
| 39 |
25160618 | Targeting of splice variants of human cytochrome P450 2C8 (CYP2C8) to mitochondria and their role in arachidonic acid metabolism and respiratory dysfunction. | 2014 Oct 24 |
1 |
| 40 |
25177037 | Losartan competitively inhibits CYP2C8-dependent paclitaxel metabolism in vitro. | 2014 |
1 |
| 41 |
25275030 | Resveratrol augments paclitaxel treatment in MDA-MB-231 and paclitaxel-resistant MDA-MB-231 breast cancer cells. | 2014 Oct |
1 |
| 42 |
23536207 | Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. | 2013 Jul |
8 |
| 43 |
23629743 | The tyrosine kinase inhibitor nilotinib selectively inhibits CYP2C8 activities in human liver microsomes. | 2013 |
1 |
| 44 |
23640974 | CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. | 2013 Jun 15 |
2 |
| 45 |
24088129 | Comparative study of polymorphism frequencies of the CYP2D6, CYP3A5, CYP2C8 and IL-10 genes in Mexican and Spanish women with breast cancer. | 2013 Oct |
1 |
| 46 |
22527101 | CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. | 2012 Jul |
2 |
| 47 |
22680343 | Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure. | 2012 Jul |
4 |
| 48 |
20212519 | Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. | 2011 Apr |
1 |
| 49 |
20848147 | Structural and functional insights into polymorphic enzymes of cytochrome P450 2C8. | 2011 Apr |
2 |
| 50 |
21056987 | Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model. | 2011 Feb |
1 |